Pasithea Therapeutics Corp. (KTTAW)
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
📈 **POSITIVE** • Medium confidence analysis (66%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (81%) **Content type:** Clinical